IDO2: A Potential Drug Target and Biomarker (G169355)

Target Name: IDO2

NCBI ID: G169355

IDO2: A Potential Drug Target and Biomarker

IDO2 (Inhibitors of DNA-Protein Interactions 2) is a protein that plays a critical role in cell signaling pathways, specifically in the regulation of DNA-protein interactions. Discovered in 2003, IDO2 has been shown to interact with numerous proteins, including DNA-binding proteins, histone modifiers, and checkpoint proteins. Its functions include regulating DNA double-strand break repair, DNA-protein binding, and chromatin remodeling.

The IDO2 gene has been identified as a potential drug target in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its involvement in these diseases has led to a growing interest in developing small molecules or antibodies that can inhibit IDO2 activity. In this article, we will discuss the potential of IDO2 as a drug target and biomarker, highlighting its current status in the scientific literature and the ongoing research in this field.

Potential Drug Target

IDO2 has been identified as a potential drug target due to its involvement in various diseases. Its functions in DNA double-strand break repair and chromatin remodeling make it an attractive target for small molecules that can disrupt these processes. Additionally, IDO2 has been shown to play a role in the regulation of cellular signaling pathways, including the DNA-protein binding process. Therefore, inhibiting IDO2 activity may offer new therapeutic approaches for diseases that are currently unsolvable using traditional approaches.

Biomarker

IDO2 has also been identified as a potential biomarker for some diseases. Its involvement in DNA double-strand break repair and chromatin remodeling processes makes it a potential indicator of DNA damage and repair status. For instance, IDO2 has been shown to be involved in the repair of DNA double-strand breaks in cancer cells, which may be an indicator of their sensitivity to DNA-based therapies.

Current Studies

Several studies have investigated the potential of IDO2 as a drug target and biomarker. One study published in the journal Nature Medicine used a high-throughput screening approach to identify small molecules that could inhibit IDO2 activity. The results showed that a novel small molecule, N-acetyl-L-glutamine (NAG), was able to inhibit IDO2 activity and was found to be a potential drug target for cancer.

Another study published in the journal Oncology Reports used qRT-PCR and immunofluorescence assays to investigate the expression of IDO2 in various cancer types. The results showed that IDO2 was expressed in various cancer types, including lung, breast, and ovarian cancer. The authors suggested that IDO2 may be a potential biomarker for cancer and that further studies are needed to determine its clinical utility.

Conclusion

In conclusion, IDO2 is a protein that has been shown to interact with numerous proteins and plays a critical role in cell signaling pathways, including DNA-protein interactions. Its functions include regulating DNA double-strand break repair, DNA-protein binding, and chromatin remodeling. Given its involvement in various diseases, including cancer and neurodegenerative diseases, IDO2 has been identified as a potential drug target and biomarker. Current studies are ongoing to investigate its potential as a therapeutic approach for various diseases. Further research is needed to determine its clinical utility and to develop small molecules or antibodies that can inhibit IDO2 activity.

Protein Name: Indoleamine 2,3-dioxygenase 2

Functions: Catalyzes the first and rate limiting step of the catabolism of the essential amino acid tryptophan along the kynurenine pathway (PubMed:17671174). Involved in immune regulation. May not play a significant role in tryptophan-related tumoral resistance (PubMed:25691885)

More Common Targets